Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceregene has presented long term follow-up data from a phase I trial of a gene therapy product that produced a 36% reduction in Parkinson's symptoms at 12 months after administration.
Subscribe to our email newsletter
The phase I trial was conducted in 12 patients who underwent stereotactic neurosurgery to deliver the product, CERE-120, into their putamen, a region of the brain affected by the degeneration of neurons in Parkinson’s disease.
This 36% improvement was maintained in both groups at the 12-month mark, the final follow-up time point in the study. Patients also demonstrated a 50% reduction in hours of “off” time, which is a time when normal Parkinson’s medication is ineffective and symptoms are troubling to the patient. Patients also experienced a doubling of good quality “on” time without dyskinesias, which is when a patient is functioning well. CERE-120 was also shown to be well tolerated in this study.
“Given the encouraging data from the phase I trial of CERE-120 in Parkinson’s disease, we are conducting a follow-on phase II clinical trial that is currently enrolling patients at nine clinical trial sites in the US,” said Raymond Bartus, Ceregene’s COO and senior vice president of clinical and preclinical R&D.
“The data from the phase I trial are reflective of the impressive results we gathered from preclinical studies, which demonstrated the ability of CERE-120 to stimulate the survival and improve the function of key neuronal cells affected by Parkinson’s disease, as well as an excellent safety profile over a wide range of CERE-120 dose levels.”